| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CK19 |
| Uniprot No | P08727 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-400aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMTSYSYR QSSATSSFGG LGGGSVRFGP GVAFRAPSIH GGSGGRGVSV SSARFVSSSS SGAYGGGYGG VLTASDGLLA GNEKLTMQNL NDRLASYLDK VRALEAANGE LEVKIRDWYQ KQGPGPSRDY SHYYTTIQDL RDKILGATIE NSRIVLQIDN ARLAADDFRT KFETEQALRM SVEADINGLR RVLDELTLAR TDLEMQIEGL KEELAYLKKN HEEEISTLRG QVGGQVSVEV DSAPGTDLAK ILSDMRSQYE VMAEQNRKDA EAWFTSRTEE LNREVAGHTE QLQMSRSEVT DLRRTLQGLE IELQSQLSMK AALEDTLAET EARFGAQLAH IQALISGIEA QLGDVRADSE RQNQEYQRLM DIKSRLEQEI ATYRSLLEGQ EDHYNNLSAS KVL |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CK19重组蛋白的假设性参考文献示例(文献为虚构，仅供格式参考)：
1. **《Recombinant CK19 protein expression and its application in cancer diagnosis》**
*作者：Zhang Y, et al. (2020)*
摘要：研究通过大肠杆菌系统高效表达CK19重组蛋白，优化纯化工艺，并验证其作为肿瘤血清标志物在ELISA检测中的敏感性和特异性，为临床诊断提供新工具。
2. **《Structural characterization of human cytokeratin 19 recombinant protein via X-ray crystallography》**
*作者：Thompson R, Garcia M. (2018)*
摘要：首次解析CK19重组蛋白的晶体结构，揭示其α螺旋结构域与肿瘤细胞粘附功能的关联，为靶向药物设计提供结构基础。
3. **《CK19 recombinant protein-based liquid biopsy for early detection of metastatic breast cancer》**
*作者：Wang L, et al. (2021)*
摘要：开发基于CK19重组蛋白的纳米抗体探针，用于富集血液中循环肿瘤细胞(CTCs)，在乳腺癌转移早期筛查中展现出高灵敏度和临床转化潜力。
4. **《Comparative study of CK19 recombinant protein production in mammalian vs. prokaryotic systems》**
*作者：Liu X, Chen H. (2019)*
摘要：对比哺乳动物细胞(CHO)与原核系统表达CK19重组蛋白的差异，发现CHO系统产物糖基化修饰更接近天然蛋白，但大肠杆菌系统成本更低且适合大规模制备。
注：以上文献为示例性虚构内容，实际研究需通过学术数据库(如PubMed、Web of Science)检索真实发表论文。
**Background on Recomcombinant CK19 Protein**
Cytokeratin 19 (CK19), a member of the intermediate filament protein family, is encoded by the *KRT19* gene and primarily expressed in simple or single-layer epithelial cells, such as those in the liver, pancreas, and intestinal tract. As the smallest (~40 kDa) and most acidic cytokeratin, CK19 plays a structural role in maintaining cell integrity and resilience while participating in cell migration, differentiation, and signaling. Its expression is tightly regulated during development and tissue repair, making it a marker for epithelial progenitor cells, including hepatic progenitors in liver regeneration.
CK19 gained clinical significance as a tumor biomarker due to its overexpression in carcinomas (e.g., breast, lung, colorectal). Circulating tumor cells (CTCs) or tumor-derived nucleic acids containing CK19 are detectable in blood, aiding cancer diagnosis and monitoring. However, its utility is context-dependent, as low CK19 levels occur in normal tissues and some malignancies.
Recombinant CK19 protein is produced via genetic engineering, often using *E. coli* or mammalian expression systems. The purified protein retains epitopes for antibody binding, enabling applications in diagnostics (e.g., ELISA kits for cancer screening) and research. Scientists employ it to study epithelial-mesenchymal transition (EMT), metastasis mechanisms, and drug responses. In therapeutics, CK19-derived peptides are explored as cancer vaccine targets or CAR-T cell therapy antigens. Additionally, it serves as a reference standard in biomarker validation and monoclonal antibody production. Despite challenges like post-translational modification differences in prokaryotic systems, recombinant CK19 remains pivotal in bridging basic research and clinical oncology.
×
